Last reviewed · How we verify

NCT04598048: EMMACE-XL

Quality of Life Post-ACS in Participants from EMMACE

Completed Last updated 30 March 2025
What this trial tests

trial testing Questionnaire in Cardiovascular Diseases in 13,400 participants. Completed in 8 November 2024.

Timeline
27 September 2020
Primary endpoint
31 March 2021
8 November 2024

Quick facts

Lead sponsorUniversity of Leeds
StatusCompleted
Study typeOBSERVATIONAL
Enrollment13,400
Start date27 September 2020
Primary completion31 March 2021
Estimated completion8 November 2024
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

University of Leeds

Who can join

Eligibility, any sex, with Cardiovascular Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

EMMACE-XL will recruit participants who are survivors of acute coronary syndrome (a type of heart attack) to assess their health-related quality of life five years or more after their heart attack. We will invite surviving participants from the EMMACE 3 and 4 studies to consent to participate in EMMACE-XL study, they will be asked to complete one questionnaire relating to their health, medication and lifestyle. The questionnaire will be linked to their data collected as part of the EMMACE 3 and 4 studies including long term follow up data from NHS Digital. The data collected from all the studies will then be analysed to see if patient groups can be identified who are at risk of poorer quality of life and worse health outcomes. These groups can then be targeted with the aim of improving their health outcomes. The study will use statistical methods to look at the relationship of factors such as; medication adherence, comorbidities and patient demographics on health-related quality of life and health outcomes.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Sex differences in health-related quality of life trajectories following myocardial infarction: national longitudinal cohort study.
    Dondo TB, Munyombwe T, Hall M, Hurdus B, et al · · 2022 · cited 6× · PMID 36351712 · DOI 10.1136/bmjopen-2022-062508

Verify or expand the search:

Other trials of Questionnaire

Trials testing the same drug.

Other recruiting trials for Cardiovascular Diseases

Currently open trials in the same condition.

Other University of Leeds trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04598048.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing